LBTI patentiertes Brustkrebs Früherkennungssystem! - 500 Beiträge pro Seite

[morchel]

First Warning(TM) heißt das Brustkrebs Früherkennungssystem wird zum Test an Argentinische Kliniken ausgeliefert.
Die testergebnisse werden voraussichtlich Ende 2001 erwartet! sollten diese positiv sein wird unverzüglich der FDA Test angestrebt!

ein Zockermäßiger "LONG"

morchel

LBTI ist ein Bestandteil der Sektion OTC&BIO auf meiner Homepage http://www.zockstocks.de.vu

[habkeingeld]

hi morchel
ist schon komisch mit Dir bin seit 03.2000 in LBTI drin und warte mal ab was passiert,vor allem die
Ergebnisse in Argentinien.
http://www.lbti.com/

RENO, Nev.--(BUSINESS WIRE)--Sept. 5, 2000--Jim Holmes, chief executive
officer of Lifeline BioTechnologies Inc. (NQB:LBTI), a company which has
developed
an early breast cancer detection system known as First Warning(TM),
today announced the signing of a letter of intent with a group of
Argentinean businessmen,
headed by Rudolfo Lafuente, that will lead to the formation of a joint
venture.

The joint venture will distribute Lifeline`s First Warning(TM) system in
South America, Central America and Mexico. It is expected that a formal
agreement will be
reached by November 2000. Lafuente stated, ``Distribution of the First
Warning(TM) System in Argentina will be targeted to begin by March
2001.``

At a meeting recently held in Buenos Aires, the city chosen as
headquarters for the Lifeline joint venture operations, representatives
of a prominent international
investment banking firm, with offices in Argentina, indicated its
willingness to fund the project subject to reviewing the preliminary
prospects for the new venture.

Lafuente indicated the business model would be completed by November and
available to the investment bankers at that time.

Lafuente said the particulars for the joint venture, including the
business model, sales levels and funding requirements, are being
prepared by the Argentinean participants
who will manage the venture. Lifeline will supply monitor components,
computer hardware and software that will be assembled in South America
at a site to be chosen.

Lifeline will retain the proprietary neural net reading service and its
computer software at its two sites in the United States. All data
collected by the physicians,
worldwide, will be transferred to and from the reading service via the
Internet. In most cases the interpretation of data submitted by the
physicians will be returned
immediately, all others in less than 24 hours.

Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: The statements contained herein that are not historical are
forward-looking
statements that are subject to risks and uncertainties that could cause
actual results to differ materially from those expressed in the
forward-looking statements,
including, but not limited to, certain delays beyond the company`s
control with respect to delays in testing and evaluation, completion of
the clinical trials, positive results
of the clinical trials, government approval, market acceptance of new
technologies or products and other risks.

Contact:

Lifeline BioTechnologies Inc.
Jim Holmes, 775/324-1933
775/852-7551 fax
[e-mail]



gruss habkeingeld

[morchel]

Wenn das was wird, dann kanst du deinen Nick Tauschen in habvielgeld

Gruß aus A

Morchel

[morchel]

Lifeline BioTechnologies Inc.: New Hope in Breast Cancer Screening
RENO, Nev.--(BUSINESS WIRE)--Oct. 11, 2000--The president of Lifeline BioTechnologies Inc. (NQB:LBTI), William Reeves, today stated that all clinical results to date indicate that CAPP(TM), the new proprietary Computer Assisted Physiological Profile(TM), developed by Lifeline as part of its First Warning(TM) system, may be at least as effective in the early detection of breast cancer as the PAP smear has been for detecting cervical cancer.
The PAP smear has reduced cervical cancer deaths by 70 percent.

Until the advent of CAPP(TM), mammography, which provides the physician an X-ray picture of the breast, has been far and away the most effective means of screening for breast cancer.

This was underscored recently by an article in the April issue of the Archives of Medicine. Dr. Sandra Ayers(a) reported on her recent investigation of "benign" tumors found by mammography, concluding that "Many of the cancers found by mammography screening have excellent prognosis, not just because of early detection, but also because many of the cancers are relatively benign, requiring minimal therapy."

However, her conclusions regarding the efficacy of the cure of breast cancers by "early detection" via mammography and prompt treatment rest on the belief that all breast cancers grow at the same rate.

In fact, some cancers have been shown by CAPP(TM) to grow rapidly, while others grow slowly. In particular, mammography screening may often detect slow-growing, non-aggressive tumors that might not be found to be malignant until much later, if at all.

R. Doll and R. Peto(b) contend that these slow-growing cancers are histologically malignant, meaning the malignancy resides within the tissue itself, but that they are benign relative to the entire biological organism.

If this is true, such tumors can often fail to be diagnosed at this early stage as the malignant tumors they are actually slowly developing into.

Reeves believes that CAPP(TM) and its First Warning(TM) system may furnish an answer to the question of the importance of the difference in tumor growth rates, since, unlike mammography, CAPP(TM) is a physiological profile of the breast tissue activity over time.

This may provide early differentiation and detection of whether a particular tumor is aggressive in its growth or slow growing and thus relatively benign.

Data of this nature in the form of a simple test has never been available to physicians before.

If Lifeline`s theory about the relevance of the rates of tumor growth to their malignancy is true, this could change the entire way in which we look at breast cancer screening and provide a method of identifying breast cancer at a significantly earlier pathological stage than any other currently available diagnostic procedure.

Lifeline is conducting ongoing testing and research in this important area.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein that are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to delays in testing and evaluation, completion of the clinical trials, positive results of the clinical trials, government approval, market acceptance of new technologies or products and other risks.

(a) Sandra Moody-Ayers M.D. (Robert Wood Johnson Clinical Scholar, Yale University School of Medicine) et al, "Benign" Tumors in Mammographically Screened Patients of a Natural Cohort with Breast Cancer, Archives of Medicine, April 2000.

(b) R. Doll and R. Peto (world-renowned cancer researchers), 1981, "Causes of Cancer: Quantitative Estimates of Avoidance of Cancer in the U.S. Today," Journal of National Cancer Institute, Vol. 66, pp. 1191-1308.


morchel

[habkeingeld]

wird sicher ab november interessant wenn sie die
joint venture zusammenarbeit und kapitalzufluß
melden.BB rückkehr im 1. quartal.e mail stammt vom dienstag.

habkeingeld

We`re trying to get the audit completed this month..... certainly by sometime
in November. With the completion of the audit and the filing of our Form
10SB we expect a return to the BB sometime during the 1st Quarter of 2001.
We`re told the review process of the Form 10SB by the SEC takes 2 to four
months.

Thanks for your continued interest in Lifeline.

Regards, Jim Holmes, CEO

[morchel]

Jim Holmes...ist das nicht ein Pornostar....ach nein der hieß ja John



morchel

[shaman]

morchel,
john, isch abe scho lang tot.

ich glaub, der hat sich zu Tode gef.....


shaman

[habkeingeld]

LBTI News



Lifeline BioTechnologies Early Detection With More Powerful
Computer System

RENO, Nev., Oct 16, 2000 (BUSINESS WIRE) -- William Reeves,
president of Lifeline BioTechnologies Inc. (NQB:LBTI), a company
which has developed an early breast cancer detection system known
as First Warning(TM), today announced that construction has begun
of its third neural network to further augment its proprietary analytical
computer system called Chrononet(TM).

Unlike most computer programs that require program designers to
establish values, which will be considered positive, neural networks
are self-learning; they are not pre-programmed.

The neural network will glean all pertinent data from each
pathologically proven breast cancer case used in its training series.
This data allows the network to identify images and patterns related to
actual cancer cases. This new screening test for breast cancer is
known as CAPP(TM) (Computer Assisted Physiological Profile).

Reeves indicated the company`s computer programmers have been
anxiously awaiting the new data, which is being generated in
Argentina where the company is presently conducting its final phase
of clinical trials.

Jim Holmes, CEO of Lifeline BioTechnologies, stated, "The beauty of
neural networks is their self-learning capability, coupled with their
ability to instantly `look` at the data and differentiate patterns and
images, which are not readily evident to the human observer. This self-learning ability allows
them to select and store information about each new cancer that is `viewed` and added to the
system, thus making the system more and more powerful as time goes on."

Eighteen hundred women are being tested with CAPP(TM) in eleven sites in Argentina.
Lifeline expects to continue testing in the U.S. in the near future. The new data from these
clinical trials will enable the CAPP(TM) system to yield even more accurate results in profiling
various breast pathologies, according to Holmes. The broader and more inclusive the
information which is used in training these neural nets, the more precisely the system will
perform in detecting breast cancer.

Reeves and Holmes both believe that eventually, and within a relatively short period of time,
Lifeline will possess the largest database in the world containing actual observations of breast
cancer physiology. They predict that CAPP(TM) will take its place as a standard for the
detecting high-risk breast cancer cases, as the PAP smear did for cervical cancer, with
comparable results in saving lives. Completion of the clinical trials and FDA clearance is
anticipated next year.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The
statements contained herein which are not historical are forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ materially from
those expressed in the forward-looking statements, including, but not limited to, certain
delays beyond the company`s control with respect to delays in testing and evaluation,
completion of the clinical trials, positive results of the clinical trials, government approval,
market acceptance of new technologies or products and other risks.

CONTACT: Lifeline BioTechnologies
Jim Holmes, 775/324-1933
Fax: [phone]
Email:[e-mail]
Web site: www.lbti.com
or
Stock Enterprises (Investor Relations)
Jim Stock, 702/614-0003

gruss habkeingeld

[habkeingeld]

hi morchel
wie gefällt Dir das während die meisten Bio´s heute keine gewinne verzeichnen konnten

Lifeline Biotechnologies Inc (LBTI)

As of Oct 19 3:55:32 PM (E.T.)
Last
0.25
Open
0.17
High
0.25
Low
0.17
Yesterday Close
0.19
Volume
265.10K



Change
0.06
% Change
31.58%
52 Week High
0.63
52 Week Low
0.05

gruss habkeingeld

[morchel]

gefällt mir gar nicht....habe nämlich keine LBTI



aber für dich freue ich mich!

Eines verrate ich noch

Stock of the week wird eine aktie die in die selbe Schiene passt!
morgen ist es soweit!

morchel

[habkeingeld]

hi morchel schau mal in dein postfach

[habkeingeld]

LBTI News

Monday October 23, 9:00 am Eastern Time
Press Release
Lifeline`s New Theories on Breast Cancer Confirmed
RENO, Nev.--(BUSINESS WIRE)--Oct. 23, 2000--The president of Lifeline BioTechnologies Inc. (NQB:LBTI), William Reeves, returned last week from a Special Conference sponsored by the American Association for Cancer Research which was held in Traverse City, Mich., and was attended by 400 of the leading cancer researchers from around the world.

This four-day conference was co-chaired by Dr. Judah Folkman of Children`s Hospital Harvard Medical School and Dr. David A. Cheresh of The Scripps Research Institute in La Jolla, Calif. The title of the Conference was ``Angiogenesis and Cancer.`` (``Angiogenesis`` means the formation and growth of new blood vessels.)

Reeves was particularly enthusiastic about a presentation by Dr. Donald McDonald of the University of California in San Francisco regarding breast cancer tumor neo-angiogenesis and microcirculation (blood flow within the smallest vessels of the body, such as capillaries), in which Dr. McDonald shared exciting data about ``The Mechanism of Tumor Vessel Leakiness,`` which confirmed Lifeline`s own thesis.

Lifeline has long claimed that tumor vessel leakiness is the major contributing factor of and constitutes the ``first warning`` that can be detected when a cancer is forming. Lifeline`s proprietary First Warning(TM) system enables the detection of this factor via its patented Computer Assisted Physiological Profile (CAPP(TM)), which makes possible, for the first time, the early detection of women who are at risk for breast cancer.

Said Reeves, ``I am grateful that we had the opportunity to attend this important conference and to share, one on one, our ideas about improving breast cancer detection. I can now state that there is absolutely no question that tumor growth and metastasis are critically dependent upon the process of angiogenesis.``

(``Metastasis`` is the spread or proliferation of the cancer to other parts of the body.)
Reeves went on to say that without the use of Lifeline`s CAPP(TM) to detect the early warning markers that angiogenesis provides, there is currently no viable method of determining whether a woman is at risk for breast cancer.

Jim Holmes, CEO of Lifeline, said that the twenty 45-minute presentations and the Q & A sessions following each, yielded a wealth of new ideas and supportive information that Lifeline can add to its interpretive neural computer systems. ``We will be able to provide physicians with more reliable, usable information about the actual physiology of breast cancer, and in a much earlier stage of its development, than they have ever had before.``

``Our participation in meetings such as this are invaluable to Lifeline and provide a unique opportunity for us to discuss novel ideas with some of the greatest minds in our field,`` added Holmes. ``It is rare for a small company like Lifeline to have an opportunity to participate in a dialogue between world-renowned research scientists in vascular and molecular biology and discuss issues that are pertinent to Lifeline`s scientific thesis.``

Reeves and Holmes anticipate completion of Lifeline`s final phase of clinical trials -- now being conducted in Argentina and the United States -- and FDA clearance in 2001.

Holmes noted that Lifeline had been interviewed by CEOCAST, a webcast company. A live audio interview of Holmes and Reeves can be heard by signing onto www.ceocast.com. The opportunity to listen to the interview may only be available for a few days. Holmes said Lifeline is attempting to get the audio interview posted on its own website.

[habkeingeld]

hallo LBTI freunde
LBTI RT bei 0,27 =42% gegenüber eröffnung bei 0,18
wer ist da reingekommen??
naja volumen ist sehr schwach

[habkeingeld]

FREE Complaint Site
Monday October 30, 9:20 am Eastern Time

Press Release
Breast Cancer Detection Aided by Breakthrough in Confidentiality of Internet Communications
RENO, Nev.--(BUSINESS WIRE)--Oct. 30, 2000--Lifeline BioTechnologies, Inc. (NQB:LBTI), a company which has developed an early breast cancer detection system known as First Warning(TM), and its wholly owned subsidiary, the Virtual Apothecary, announced today they have passed yet another milestone in the finalization of their proprietary communications software with the internal development of their new ``core`` database software.

This new software includes proprietary encryption algorithms that will prevent interception and interpretation of patient data communicated from computer to computer over the Internet.

William Reeves, President of Lifeline, said that the software engines completed this week form the foundation upon which the Virtual Apothecary and Lifeline BioTechnologies will communicate patient data as well as information on test results to and from their physician clients. ``It was exciting to see them operational,`` he said. ``This will ensure absolute confidentiality of patient data at every step as it is transmitted to Lifeline and test results are delivered back to the physician`s office.``

Reeves added, ``Physicians have always been leery about communicating confidential patient information over the Internet for privacy reasons. Now, with this new encryption software, we can give our physician clients complete assurance that any such fears are groundless.``

During a test conducted for Lifeline executives, communications were sent from site to site using standard Internet protocols (HTTP/TCP/IP) to demonstrate the process. ``Our basic architecture utilizes the Internet extensively,`` said Kirby Williams, developer of the software system and President of Virtual Apothecary. ``This will allow for spreading the workload responsibilities over a variety of computers which can be located anywhere in the world, while allowing administration to remain centralized.``

According to Jim Holmes, CEO of Lifeline, they are also elated that the company will not be forced to spend $100,000 for database storage equipment, nor forced to rent space from a database storage provider. ``We are so pleased and proud of what our researchers, led by Kirby Williams, have accomplished in developing this proprietary software,`` he said. ``The basic benefit, other than cost, will be in the ease of management and administration of our data base. The system as it is now formed will give us the ability to maintain communication with a million sites comfortably. There will be no bottleneck or delays in on-line communications. When clients in Japan and the Pacific Rim want to access the system, the database will not be occupied with providing the results of the day`s input from other parts of the world.``

Lifeline`s proprietary First Warning(TM) System provides a Computer Assisted Physiological Profile(TM) (CAPP) whose function of enabling earlier identification of women at high risk for development of breast cancer makes it similar to the function of a PAP smear, which has reduced cervical cancer deaths 70% in two decades.

A recent live audio interview of Holmes and Reeves by CEOCAST, a Webcast company, may be available soon at Lifeline`s site, www.lbti.com, where there are also illustrations explaining how breast cancer begins, as well as additional data about the company, its management and the progress of the final phases of their clinical trials.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company`s control with respect to delays in testing and evaluation, completion of the clinical trials, positive results of the clinical trials, government approval, market acceptance of new technologies or products and other risks

[greenberg]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]